Three‐Year Safety Results of SAR422459 (EIAV‐ABCA4) Gene Therapy in Patients With ABCA4‐Associated Stargardt Disease: An Open‐Label Dose‐Escalation Phase I/IIa Clinical Trial, Cohorts 1‐5: Results of Gene Therapy in Patients With Stargardt Disease
Maria A. Parker, Laura R. Erker, Isabelle Audo, Dongseok Choi, Saddek Mohand-Said, Kastytis Sestakauskas, Patrick Benoit, Terence Appelqvist, Melissa Krahmer, Caroline Ségaut-Prévost, Brandon J. Lujan, Ambar Faridi, Elvira N. Chegarnov, Peter N. Steinkamp, Cristy Ku, Mariana Matioli da Palma, Pierre Olivier Barale, Sarah Ayelo-Scheer, Andreas Lauer, Tim StoutDavid J. Wilson, Richard G. Weleber, Mark E. Pennesi, José Alain Sahel, Paul Yang
Dive into the research topics of 'Three‐Year Safety Results of SAR422459 (EIAV‐ABCA4) Gene Therapy in Patients With ABCA4‐Associated Stargardt Disease: An Open‐Label Dose‐Escalation Phase I/IIa Clinical Trial, Cohorts 1‐5: Results of Gene Therapy in Patients With Stargardt Disease'. Together they form a unique fingerprint.